Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor

Journal of Virology

Volumn 74, Issue 5, 2000, Pages 2451-2454

  Haan, Keith M ^a   Kwok, William W ^b   Longnecker, Richard ^a,c   Speck, Peter ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c Ward Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HLA DP ANTIGEN; HLA DQ ANTIGEN; MEMBRANE RECEPTOR; VIRUS GLYCOPROTEIN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MEMBRANE FUSION; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS RECOMBINANT; VIRUS RESISTANCE;

CELL LINE; FLOW CYTOMETRY; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 4, HUMAN; HLA-DP ANTIGENS; HLA-DQ ANTIGENS; LUMINESCENT PROTEINS; RECEPTORS, COMPLEMENT 3D; RECEPTORS, VIRUS;

EID: 0033977048     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.5.2451-2454.2000     Document Type: Article

References (35)

1. Ahearn, J. M., S. D. Hayward, J. C. Hickey, and D. T. Fearon. 1988. Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor. Proc. Natl. Acad. Sci. USA 85:9307-9311.
2. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955-1958.
3. Ameglio, F., M. R. Capobianchi, A. Dolei, and R. Tosi. 1983. Differential effects of gamma interferon on expression of HLA class II molecules controlled by the DR and DC loci. Infect. Immun. 42:122-125.
4. Basham, T., W. Smith, L. Lanier, V. Morhenn, and T. Merigan. 1984. Regulation of expression of class II major histocompatibility antigens on human peripheral blood monocytes and Langerhans cells by interferon. Hum. Immunol. 10:83-93.
5. Basta, P. V., P. A. Sherman, and J. P. Ting. 1987. Identification of an interferon-gamma response region 5′ of the human histocompatibility leukocyte antigen DR alpha chain gene which is active in human glioblastoma multiforme lines. J. Immunol. 138:1275-1280.
6. Brown, J. H., T. S. Jardetzky, J. C. Gorga, L. J. Stern, R. G. Urban, J. L. Strominger, and D. C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33-39.
7. Choe, H., M. Farzan, Y, Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
8. Collins, T., A. J. Korman, C. T. Wake, J. M. Boss, D. J. Kappes, W. Fiers, K. A. Ault, M. A. Gimbrone, Jr., J. L. Strominger, and J. S. Pober. 1984. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc. Natl. Acad. Sci. USA 81:4917-4921.
9. DeMars, R., C. C. Chang, S. Shaw, P. J. Reitnauer, and P. M. Sondel. 1984. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum. Immunol. 11:77-97.
10. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
11. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158.
12. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, and W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
13. Epstein, M. A., B. G. Achong, Y. M. Barr, B. Zajac, G. Henle, and W. Henle. 1966. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji). J. Nat. Cancer Inst. 37:547-559.
14. Ettinger, R. A., A. W. Liu, G. T. Nepom, and W. W. Kwok. 1998. Exceptional stability of the HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. J. Immunol. 161:6439-6445.
15. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
16. Geraghty, R. J., C. Krummenacher, G. H. Cohen, R. J. Eisenberg, and P. G. Spear. 1998. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280:1618-1620.
17. Kieff, E. 1996. Epstein Barr virus and its replication, p. 1109-1162. In B. Fields, D. Knipe, and P. Howley (ed.), Fundamental virology. Raven Press, New York, N.Y.
18. Klein, G., G. Clements, J. Zeuthen, and A. Westman. 1976. Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle. Int. J. Cancer 17:715-724.
19. Li, Q., M. K. Spriggs, S. Kovats, S. M. Turk, M. R. Comeau, B. Nepom, and L. M. Hutt-Fletcher. 1997. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J. Virol. 71:4657-4662.
20. Li, Q., S. M. Turk, and L. M. Hutt-Fletcher. 1995. The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. J. Virol. 69:3987-3994.
21. Li, Q. X., L. S. Young, G. Niedobitek, C. W. Dawson, M. Birkenbach, F. Wang, and A. B, Rickinson. 1992. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 356:347-350.
22. Liebowitz, D. 1998. Pathogenesis of Epstein-Barr virus, p. 175-199. In D. J. McCance (ed.), Human tumor viruses. ASM Press. Washington, D.C.
23. Long, E. O., S. Rosen-Bronson, D. R. Karp, M. Malnati, R. P. Sekaly, and D. Jaraquemada. 1991. Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum. Immunol. 31:229-235.
24. Longnecker, R. 1998. Molecular biology of Epstein-Barr virus, p. 135-174. In D. J. McCance (ed.), Human tumor viruses. ASM Press, Washington, D.C.
25. Montgomery, R. I., M. S. Warner, B. J. Lum, and P. Spear. 1996. Herpes simplex type 1 entry mediated by a novel member of the TNF/NGF receptor family. Cell 87:427-436.
26. Morikawa, S., E. Tatsumi, M. Baba, T. Harada, and K. Yasuhira. 1978. Two E-rosetle-forming lymphoid cell lines. Int. J. Cancer 21:166-170.
27. Nemerow, G. R., R. A. Houghten, M. D. Moore, and N. R. Cooper. 1989. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369-377.
28. Paterson, R. L., C. Kelleher, T. D. Amankonah, J. E. Streib, J. W. Xu, J. F. Jones, and E. W. Gelfand. 1995. Model of Epstein-Barr virus infection of human thymocytes: expression of viral genome and impact on cellular receptor expression in the T-lymphoblastic cell line, HPB-ALL. Blood 85:456-464.
29. Rickinson, A., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
30. Speck, P., K. A. Kline, P. Cheresh, and R. Longnecker. 1999. Epstein-Barr virus lacking latent membrane protein 2 immortalizes B cells with efficiency indistinguishable from wild-type virus. J. Gen. Virol. 80:2193.
31. Speck, P., and R. Longnecker. 1999. Epstein-Barr virus (EBV) infection visualized by EGFP expression demonstrates dependence on known mediators of EBV entry. Arch. Virol. 144:1123-1137.
32. Spriggs, M. K., R. J. Armitage, M. R. Comeau, L. Strockbine, T. Farrah, B. Macduff, D. Ulrich, M. R. Alderson, J. Müllberg, and J. I. Cohen. 1996. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR β chain and inhibits antigen presentation. J. Virol. 70:5557-5563.
33. Tanner, J., J. Weis, D. Fearon, Y. Whang, and E. Kieff. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50:203-213.
34. Tedder, T. F., V. S. Goldmacher, J. M. Lambert, and S. F. Schlossman. 1986. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. J. Immunol. 137:1387-1391.
35. Wang, X., and L. M. Hutt-Fletcher. 1998. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J. Virol. 72:158-163.